Durable, potentially curative therapies for genetic disorders and cancer have arrived. Short—even single dose—treatment regimens yield lasting health benefits, but large single payments will challenge the current reimbursement system.

Policy, regulations, and business operations need to evolve to enable emerging solutions. Now is the time to implement precision financing solutions to ensure patient access and system sustainability.

Featured keynotes

Senator Bill Cassidy
Senator Sheldon Whitehouse

Who’s joining this widely attended event

• **Policymakers / legislators** on the Hill to identify the challenges patients are going to face and make sure they have access to transformational therapies
• **Industry senior leaders and heads of government affairs** to help articulate challenges and shape direction for future of innovation.
• **Regulators** to evolve the system based on new strategies and emerging tools
• **Payers** to learn new financing models
• **Patients and providers** to advocate for progress and access

**FoCUS**

Financing and Reimbursement of Cures in the US

Hosted by
MIT Center for Biomedical Innovation
NEWDIGS Initiative

Sponsored by
Financing and Reimbursement of Cures (FoCUS) Project,
Alliance for Regenerative Medicine, National Pharmaceutical Council, MedImpact, Anthem, Pfizer, and FasterCures